hypothyroidism
Do not screen asymptomatic adults (CTFPHC 2019). Start levothyroxine 1.6 µg/kg/day in young healthy adults with overt primary hypothyroidism, or 25–50 µg/day in older adults / CAD, rechecking TSH in 4–6 weeks. In subclinical hypothyroidism, treat if TSH >10 mU/L, pregnancy/planning, or selected symptomatic younger adults — not routinely in adults ≥65 (TRUST (2017)). Always exclude adrenal insufficiency before starting LT4 in suspected central hypothyroidism.
screening and diagnosis
- CTFPHC 2019: strong recommendation against routine TSH screening in asymptomatic non-pregnant adults ≥18. Does not apply to patients with prior thyroid disease/surgery, neck radiation, RAI, pituitary disease, or thyroid-active drugs (lithium, amiodarone, immune checkpoint inhibitors).
- Primary vs central:
- Primary overt: elevated TSH + low free T4 (Hashimoto thyroiditis is the commonest cause in iodine-replete regions; routine anti-TPO testing is unnecessary once overt hypothyroidism is diagnosed).
- Central (secondary/tertiary): low free T4 with low or inappropriately normal TSH → never rely on TSH to diagnose or titrate central disease; evaluate the remaining pituitary axes (especially morning cortisol) and order pituitary MRI → pituitary disorders.
- Non-thyroidal illness syndrome (euthyroid sick): avoid testing TSH/T4 in acutely ill hospitalised patients unless true thyroid disease is strongly suspected (typically low T3, normal/low T4, normal/low TSH; recovers without LT4 — ATA 2014 recommends against treatment).
levothyroxine initiation and titration
Levothyroxine (LT4) monotherapy is standard of care (ATA 2014 recommends against routine LT4/LT3 combination, LT3 monotherapy, desiccated thyroid extract, or compounded thyroid hormones).
| clinical scenario | starting LT4 dose | monitoring & target |
|---|---|---|
| young, healthy, overt primary | 1.6 µg/kg/day (full replacement) | recheck TSH in 4–6 weeks; target normal reference range |
| elderly (>65 y), frail, or CAD/arrhythmia | 25–50 µg/day (or 12.5–25 µg if severe CAD); titrate by 12.5–25 µg q4–6 weeks | avoids precipitating angina or AF; target upper half of normal TSH (e.g. 4–6 mU/L) in frail older adults |
| central hypothyroidism | weight-based (start low if older/CAD) AFTER excluding/treating AI | titrate by free T4 (upper half of normal range), never TSH |
| pregnancy | increase pre-pregnancy dose by ~25–30% at positive test | see thyroid disease in pregnancy |
In suspected central hypothyroidism, ICI hypophysitis, or autoimmune polyglandular syndrome, starting LT4 accelerates cortisol metabolism and can precipitate adrenal crisis. Check morning cortisol / start glucocorticoids first.
subclinical hypothyroidism (SCH)
Elevated TSH with normal free T4 (confirm with repeat TSH + free T4 in 2–3 months, as mild elevations often normalise spontaneously). Anti-TPO antibodies help stratify progression risk (~4%/year if TPO+ vs ~2%/year if TPO−).
| TSH & context | management | rationale |
|---|---|---|
| TSH >10 mU/L | treat with LT4 | higher progression to overt disease, dyslipidaemia, and CV/HF risk |
| TSH 4.5–10 mU/L, age <65 | consider LT4 if clearly symptomatic, goitre, TPO+, or planning pregnancy | trial 3–6 months; stop if symptoms do not improve |
| TSH 4.5–10 mU/L, age ≥65 | do not routinely treat (observe) | TRUST (2017) (n = 737, ≥65 y, TSH 4.6–19.9) showed no improvement in hypothyroid symptoms or tiredness; overtreatment causes AF and bone loss |
| pregnancy | specific thresholds apply | see thyroid disease in pregnancy |
persistent TSH elevation on levothyroxine
When TSH stays high despite escalating LT4 doses (>1.6–2.0 µg/kg/day), check in order:
- Adherence (commonest cause — supervised weekly dosing or pill counts if suspected).
- Timing & absorption interference: take LT4 on an empty stomach 30–60 minutes before breakfast (or at bedtime ≥3 h after food) and separate by ≥4 hours from calcium, iron, bile acid sequestrants, sucralfate, phosphate binders, and antacids. PPIs, H. pylori gastritis, and coeliac disease impair gastric acid–dependent absorption.
- Increased clearance or TBG binding: oestrogen therapy (oral MHT/OCP increases TBG → higher LT4 need; transdermal oestrogen has minimal effect), rifampin, carbamazepine, phenytoin, phenobarbital, sertraline, tyrosine kinase inhibitors.
- Weight gain or formulation switching (keep brand consistent when TSH is tightly titrated).
Prepared 2026-11-19. Not yet verified — check every number against the sources.